Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study
As of late December 2025, Health Canada had nine active applications from companies that want to sell generic semaglutide
We may earn a small commission on some links at no extra cost to you
Non-Economic Damages: This includes compensation for emotional distress and loss of enjoyment of life due to the impact of the condition
The NDA reflects accumulated evidence on: Efficacy in weight management Safety and tolerability profile Manufacturing controls and product quality Benefit-risk assessment in target populations As outlined in FDA guidance on obesity drug development, long-term weight management therapies are evaluated not only on efficacy but also on sustained outcomes, safety margins, and real-world usability
Diabetes and PD Diabetes induces mitochondrial dysfunction, which is a key feature of PD pathology [18, 19]